11514371

Source:http://linkedlifedata.com/resource/pubmed/id/11514371

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0034975, umls-concept:C0288672, umls-concept:C0376495, umls-concept:C0592046, umls-concept:C1274040
pubmed:issue	8
pubmed:dateCreated	2001-8-21
pubmed:abstractText	Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of percutaneous coronary intervention. This registry was conducted to characterize the effects of repeated administration of abciximab during intervention.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0147763
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Aspirin, http://linkedlifedata.com/resource/pubmed/chemical/Heparin, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa..., http://linkedlifedata.com/resource/pubmed/chemical/abciximab
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1524-4539
pubmed:author	pubmed-author:BradenG AGA, pubmed-author:CinesD BDB, pubmed-author:DamarajuLL, pubmed-author:EffronM BMB, pubmed-author:GeorgeB SBS, pubmed-author:JordanR ERE, pubmed-author:KereiakesD JDJ, pubmed-author:KleimanN SNS, pubmed-author:LangrallM AMA, pubmed-author:LincoffA MAM, pubmed-author:MascelliM AMA, pubmed-author:SaneD CDC, pubmed-author:SchantzAA, pubmed-author:TchengJ EJE
pubmed:issnType	Electronic
pubmed:day	21
pubmed:volume	104
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	870-5
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:11514371-Angioplasty, Balloon, Coronary, pubmed-meshheading:11514371-Antibodies, pubmed-meshheading:11514371-Antibodies, Monoclonal, pubmed-meshheading:11514371-Aspirin, pubmed-meshheading:11514371-Coronary Disease, pubmed-meshheading:11514371-Disease-Free Survival, pubmed-meshheading:11514371-Drug Administration Schedule, pubmed-meshheading:11514371-Hemorrhage, pubmed-meshheading:11514371-Heparin, pubmed-meshheading:11514371-Humans, pubmed-meshheading:11514371-Immunoglobulin Fab Fragments, pubmed-meshheading:11514371-Platelet Aggregation, pubmed-meshheading:11514371-Platelet Aggregation Inhibitors, pubmed-meshheading:11514371-Platelet Glycoprotein GPIIb-IIIa Complex, pubmed-meshheading:11514371-Postoperative Complications, pubmed-meshheading:11514371-Registries, pubmed-meshheading:11514371-Thrombocytopenia, pubmed-meshheading:11514371-Treatment Outcome, pubmed-meshheading:11514371-United States, pubmed-meshheading:11514371-Vascular Patency
pubmed:year	2001
pubmed:articleTitle	Abciximab readministration: results of the ReoPro Readministration Registry.
pubmed:affiliation	Duke Clinical Research Institute, Durham, NC, USA. tchen001@mc.duke.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase IV